U.S. Markets closed

Sino Biopharmaceutical Limited (SMZ1.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.5648+0.0040 (+0.71%)
At close: 11:59AM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5608
Bid0.5662 x 1111100
Ask0.5860 x 1111100
Day's Range0.5648 - 0.5660
52 Week Range0.4400 - 0.6496
Avg. Volume619
Market Cap4.546B
Beta (5Y Monthly)N/A
PE Ratio (TTM)17.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters

    China's CanSinoBIO H1 revenue drops on weaker COVID shot demand

    China's CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine makers affected by waning demand for their shots. The decline from 2.06 billion yuan ($299.8 million) to 629.8 million yuan was mainly driven by weaker COVID vaccine demand as growth in global uptake slowed and price changes of CanSinoBIO's products, the firm said in a company filing published on Sunday. CanSinoBIO, which sells a one-dose shot in countries including China and Mexico and is seeking approval for an inhaled version of the vaccine, said half-year net profit dropped by 98.7% year-on-year.

  • Zacks

    F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

    Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.

  • Benzinga

    F-star Therapeutics Shares Are Rallying Today - Read Why

    invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ: FSTX) for $7.12 per share. The proposed acquisition values F-star at approximately $161 million. Just a year ago, F-star priced its IPO at $7. F-star's next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharma's existing capabilities and reinforces its global oncology pipeline. Four programs are progressing in the clinic, three based on